Fmr1 Cgg Editing Cgg Triplet Repeats Using Endonuclease For Targeting Fragile X Mental Retardation 1

Full-text?

The full document isn't yet available to us from the patent office.

Abstract

The present invention relates to correction of a CGG repeated base sequence region using endonuclease for targeting a fragile X mental retardation 1 (FMR1) gene, and treatment of a fragile X syndrome using the same. The correction of a CGG repeated base sequence region of the present invention is abnormal CGG repeated deletion-mediated correction ensured by using non-homologous end joining (NHEJ) derived by an endonuclease without using an exogenous donor sequence for homologous recombination or without using a wild-type allele.


Claims

Information currently unavailable.

Document Preview
No Image Yet
Document History
  • Publication: Mar 20, 2017
  • Application: Sep 9, 2015
    KR KR 20150127904 A
  • Priority: Sep 9, 2015
    KR KR 20150127904 A

Download Citation


Sign in to the Lens

Feedback